# Study Evaluating Bifeprunox in Patients With Schizophrenia.

> **NCT00366327** · PHASE3 · TERMINATED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 400 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Bifeprunox

## Key facts

- **NCT ID:** NCT00366327
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2013-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00366327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00366327, "Study Evaluating Bifeprunox in Patients With Schizophrenia.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00366327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*